Merck Wins Patent Ruling Over Sandoz Version of Cancidas

Merck & Co. won a judge’s ruling that could help it block Novartis AG’s Sandoz unit from selling a generic copy of its Cancidas antifungal treatment until a patent expires in 2017.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.